Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 528

Investment opportunities in markets priced at extremes

Global equities feature three key ingredients at the moment: a concentrated market, wide valuation dispersions and different cyclical and structural opportunities. Investors have gone through a tough interest rate tightening cycle but monetary policy acts with a lag, and the delayed reaction is coming through in leading indicators. But at the same time, we have the US Treasury and politicians expanding the fiscal deficit, which is one reason why inflation is staying sticky.

Market valuations and policy variations

Factors are working against each other with a lot of policy volatility and variations in nominal GDP growth. What happens to market multiples in that environment? In the 1970s, the Price/Earnings ratio averaged around 11 times in US broad equities. That wasn't just because the discount rate was higher because we had inflation. It was because of this volatility and it derated equities (that is, lowered P/Es). Today, the P/E multiple is 30 times. The takeaway is that US equities are offering a narrow margin of error based on valuations today and the inflation and rate regime that we've shifted into.

Let's talk factors. In the chart, the yellow line is what many investors think about as the value factor. We refer to it as valuation dispersion between value and growth. The yellow line is tracking the multiple paid for the lowest P/E stocks in the market by quintile versus the highest. It's been trending down for a dozen years, so there's a lot of valuation dispersion in the market today.

Owning quality or growth is more expensive than normal. While we know investors should pay a higher multiple for those characteristics, they are paying a very high multiple today. Is it durable growth and durable quality?

Multiple dispersion is wide and value stocks are cheap

Market cap concentrations

Another observation is that market cap concentration is going through a crazy period that will not last. We’ve seen it before, from 1990 in Japanese equities, 2000 in US tech stocks and today, it's concentrated in the Magnificent Seven. The average is P/E multiple is about 36 times, with Tesla on a really high multiple and Meta and Alphabet on much lower multiples. But we're seeing a concentration of profit in the economy in a small number of companies.

Market capitalisation concentration also high

Everything else is on a lower multiple and the more we move away from the US, the lower that multiple goes. So, arguably, there are many sectors in many regions that are already pricing in a relatively hard landing.

Why have the Magnificent Seven re-rated? Will Alphabet or Meta sell more digital ads in a recession than they do today? Will Tesla sell more cars in a recession? Investors must be very certain that the high multiple is justified and we argue conditions will be tougher. Now, we also have companies in that group that are arguably more defensive, such as Microsoft. It's got a great business and AI is giving it more pricing power.

Past winners often fall behind

So is it rational to play defense in some of these companies that are maturing, that are becoming more economically sensitive? Let's do a history lesson. In 1980, the number 1 company in the world was IBM, effectively the inventor of the PC. But IBM was famously dependent on two other companies, Intel for chips and Microsoft for the operating system. It saw those two companies as suppliers.

Now let's go to 1990. The biggest company in the world was NTT, a very boring company. It's the Japanese equivalent of Telstra. Then by 2000, IBM has been disrupted by its two suppliers. Microsoft and Intel which have taken all of that profit pool in personal computing. Then coming out of the GFC, China delivered a massive stimulus and companies exposed to China became the largest companies in the world. Today, Apple has brought desktop computing power to our fingertips on a mobile device.

Investors should expect a reshuffling of winners

The point of this history lesson is the top 10 companies are constantly turning over because of the competitive dynamic in the market. Investors need to navigate structural and cyclical change, avoid the cyclicals that become value traps and miss the growth stocks that become growth traps as they mature, with an eye on socio and macroeconomic change.

In our portfolios there are four pillars:

  1. Lower-growth companies have a role at multiples where they're attractive investments.
  2. Companies that are transitioning into strong structural growth.
  3. Defensive or secular growth companies that are benefiting from structural growth but are still mispriced relative to that growth.
  4. In our long-short fund, single stock shorts and tail risk hedges that are mispriced.

Here are some examples.

It is hard to find anyone who has a positive case for China, but valuations are at record lows and there are opportunities in really high-quality companies. For example, Alibaba today and its equivalents like Baidu, which are Chinese versions of the Magnificent Seven, are trading at 10 to 12 times earnings. They are very strong businesses, they're hard to break, they are run for shareholders, and they are priced for an extraordinarily high level of geopolitical risk and a very bad economic outcome. There's a significant margin of safety and we think there are opportunities in these companies.

In our second example, a structural transition story is Total, an oil company, but it is an oil company that has been biasing its investments towards natural gas as a transition fuel, as well as renewables. More than half of its investment is going into those areas. There has not been the supply response to higher oil prices that we've had in the past. At a 15% free cash flow yield, there is a lot of value in Total.

And then, a third area of structural change, and AI adoption is a very long-term trend. The companies that we think are in the best position to benefit from AI adoption are those ones who can monetise it with their business customers. We think it will be hard to make money out of selling AI services to consumers, but we think there is a big productivity gain for companies like Microsoft. We don't think it is priced in for Oracle, Microsoft, SAP.

The bottom line

There is a massive amount of concentration in the market, valuation dispersion is high and value as a factor is cheap. These will lead to opportunities.

Investors should avoid paying yesterday's prices to solve for tomorrow's uncertainty. Crowding into some of the Magnificent Seven is not a defensive move, and investors should be wary of the potential for economic sensitivity in some of those names.

 

Jacob Mitchell is Founder and Chief Investment Officer of Antipodes Partners, managing over $10 billion and an affiliate manager of Pinnacle Investment Management. Pinnacle is a sponsor of Firstlinks. Jacob spent 14 years at Platinum Asset Management before starting Antipodes in 2015.

This article is for general information purposes only and does not consider any person’s objectives, financial situation or needs, and because of that, reliance should not be placed on this information as the basis for making an investment, financial or other decision.

For more articles and papers from Pinnacle Investment Management and affiliate managers, click here.

 

banner

Most viewed in recent weeks

Vale Graham Hand

It’s with heavy hearts that we announce Firstlinks’ co-founder and former Managing Editor, Graham Hand, has died aged 66. Graham was a legendary figure in the finance industry and here are three tributes to him.

Australian stocks will crush housing over the next decade, one year on

Last year, I wrote an article suggesting returns from ASX stocks would trample those from housing over the next decade. One year later, this is an update on how that forecast is going and what's changed since.

Taxpayers betrayed by Future Fund debacle

The Future Fund's original purpose was to meet the unfunded liabilities of Commonwealth defined benefit schemes. These liabilities have ballooned to an estimated $290 billion and taxpayers continue to be treated like fools.

Australia’s shameful super gap

ASFA provides a key guide for how much you will need to live on in retirement. Unfortunately it has many deficiencies, and the averages don't tell the full story of the growing gender superannuation gap.

Looking beyond banks for dividend income

The Big Four banks have had an extraordinary run and it’s left income investors with a conundrum: to stick with them even though they now offer relatively low dividend yields and limited growth prospects or to look elsewhere.

AFIC on its record discount, passive investing and pricey stocks

A triple headwind has seen Australia's biggest LIC swing to a 10% discount and scuppered its relative performance. Management was bullish in an interview with Firstlinks, but is the discount ever likely to close?

Latest Updates

Investment strategies

9 lessons from 2024

Key lessons include expensive stocks can always get more expensive, Bitcoin is our tulip mania, follow the smart money, the young are coming with pitchforks on housing, and the importance of staying invested.

Investment strategies

Time to announce the X-factor for 2024

What is the X-factor - the largely unexpected influence that wasn’t thought about when the year began but came from left field to have powerful effects on investment returns - for 2024? It's time to select the winner.

Shares

Australian shares struggle as 2020s reach halfway point

It’s halfway through the 2020s decade and time to get a scorecheck on the Australian stock market. The picture isn't pretty as Aussie shares are having a below-average decade so far, though history shows that all is not lost.

Shares

Is FOMO overruling investment basics?

Four years ago, we introduced our 'bubbles' chart to show how the market had become concentrated in one type of stock and one view of the future. This looks at what, if anything, has changed, and what it means for investors.

Shares

Is Medibank Private a bargain?

Regulatory tensions have weighed on Medibank's share price though it's unlikely that the government will step in and prop up private hospitals. This creates an opportunity to invest in Australia’s largest health insurer.

Shares

Negative correlations, positive allocations

A nascent theme today is that the inverse correlation between bonds and stocks has returned as inflation and economic growth moderate. This broadens the potential for risk-adjusted returns in multi-asset portfolios.

Retirement

The secret to a good retirement

An Australian anthropologist studying Japanese seniors has come to a counter-intuitive conclusion to what makes for a great retirement: she suggests the seeds may be found in how we approach our working years.

Sponsors

Alliances

© 2024 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.